Crucially, RI‐AG03's inhibitory effect is not dependent upon interaction with the aggregation inducer, as is reported for other peptide inhibitors,79 which is an essential requirement for all potential Tau‐aggregation inhibitors as the aggregation inducer in vivo in sporadic Tauopathies is unknown so the aggregation inhibitor should be independent of the aggregation inducer. The gene discussed is MAPT; the disease is tauopathy.